BMA Earnings

BMA reported its FY2025Q3 earnings on 2025-11-26, showcasing a revenue of 864.00B against an estimate of 900.00B, resulting in a -4.09% surprise. The EPS was -0.39, surpassing the expected 0.67 by -158.21% . The stock experienced a 4.34% price change on the earnings day and a 7.16% change over the next five days, reflecting market reactions to the results.

Following BMA's FY2025Q3 earnings announcement on 2025-11-26, the stock price moved by 4.34% on the day of the release. Over the subsequent five days, it saw a 7.16% change. Historically, BMA's stock price tends to shift by an average of +4.41% in the 10 days leading up to earnings and +2.12% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BMA’s annual revenue to reach 947.00B, while the EPS is projected at 4.00K. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.61% and EPS estimates Revise Downward by -18.2% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BMA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.61%, while EPS estimates moved Revise Downward by -18.2% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BMA's stock price typically moves by +4.41% in the 10 days before its earnings and +2.12% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 4.00K and revenue of 947.00B.

The earnings call summary reveals several concerns: a rise in nonperforming loans, unexpected expenses, and poor bond portfolio performance. Despite optimistic loan and deposit growth forecasts, the Q&A section highlighted uncertainties, such as unclear management responses and no immediate buyback plans. The market may react negatively to the weak financial results, increased costs, and cautious outlook on returns. Given the mid-cap status of the company, these factors are likely to result in a stock price decrease of -2% to -8% over the next two weeks.